Treatment results of TCF induction chemotherapy followed by concurrent chemoradiotherapy in stage III-IVA nasopharyngeal carcinoma at National Cancer Hospital
Main Article Content
Abstract
Nasopharyngeal cancer (NPC) is a common head and neck cancer in Vietnam. Induction chemotherapy with the TCF regimen followed by concurrent chemoradiotherapy is a new treatment approach that increases response rates and reduces mortality due to distant metastasis in locally advanced stages. This study was conducted on 40 patients with stage III - IVA NPC treated with TCF induction chemotherapy followed by chemoradiotherapy at Vietnam National Cancer Hospital from January 2019 to December 2020. The study show that the average age was 45 ± 13, male/female ratio = 3/1, stages III and IV accounted for 60% and 40% respectively. Treatment results,87.5% response rate after induction chemotherapy. The 3-year progression-free survival and overall survival rates were 77.5% and 87.5%, respectively. Acute grade 3 or higher side effects were rare. The study shows that this treatment regimen provides promising results and relatively good tolerance. However, further research is needed to evaluate the long-term efficacy and side effects of the treatment.
Article Details
Keywords
Nasopharyngeal carcinoma, induction chemotherapy, concurrent chemoradiotherapy, TCF
References
2. Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavifar N. Nasopharyngeal cancer in the world- epidemiology, incidence, mortality and risk factors.
3. OuYang PY, Su Z, Ma XH, Mao YP, Liu MZ, Xie FY. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer. 2013; 109(12): 2987-2997. doi:10.1038/bjc.2013.659.
4. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11): 1509-1520. doi:10.1016/S1470-2045(16)30410-7.
5. Peng H, Chen B, He S, Tian L, Huang Y. Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up. Front Oncol. 2021; 11: 765378. doi:10.3389/fonc.2021.765378.
6. Liu GY, Lv X, Wu YS, et al. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun Lond Engl. 2018; 38(1): 21. doi:10.1186/s40880-018-0283-2.
7. Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2021; 39(7): 840-859. doi:10.1200/JCO.20.03237.
8. Yu H, Yin X, Mao Y, Chen M, Tang Q, Yan S. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019. Eur Arch Otorhinolaryngol. 2022; 279(3): 1519-1533. doi:10.1007/s00405-021-06922-2.
9. Xie SH, Yu ITS, Tse LA, Mang OW kong, Yue L. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: Suggestion of a potential protective role of oestrogen. Eur J Cancer. 2013; 49(1): 150-155. doi:10.1016/j.ejca.2012.07.004.
10. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol Off J Am Soc Clin Oncol. 1998; 16(4): 1331-1339. doi:10.1200/JCO.1998.16.4.1331.
11. Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol. 2010;65(3):589-595. doi:10.1007/s00280-009-1152-0
12. Takamizawa S, Honma Y, Murakami N, et al. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma. Invest New Drugs. 2021;39(2):564-570. doi:10.1007/s10637-020-00999-y
13. Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(4):546-558. doi:10.1002/cncr.29795
14. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019;381(12):1124-1135. doi:10.1056/NEJMoa1905287
15. Peng H, Chen L, Zhang Y, et al. The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Sci Rep. 2016;6:24835. doi:10.1038/srep24835
16. Ou D, Blanchard P, El Khoury C, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol. 2016;62:114-121. doi:10.1016/j.oraloncology.2016.10.011
17. Yang SS, Guo JG, Liu JN, et al. Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis. Front Oncol. 2021;10:591205. doi:10.3389/fonc.2020.591205
18. Zheng Y, Han F, Xiao W, et al. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy. Radiat Oncol. 2015;10(1):17. doi:10.1186/s13014-014-0326-z
19. Shim HJ, Kim HJ, Hwang JE, et al. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy. Medicine (Baltimore). 2020;99(49):e23173. doi:10.1097/MD.0000000000023173